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Witold Żurański , Michał Kasprzak
Department of Cardiology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Poland
Papillary fibroelastoma in a 63-year-old 
asymptomatic patient with paroxysmal 
atrial fibrillation
ABSTRACT
Papillary fibroelastoma (PFE) is the second most frequent benign cardiac tumor. It is located mainly in the 
heart valves. Because its course is usually clinically silent it is often detected accidentally in transthoracic 
echocardiography (TTE). Despite the benign nature of the lesion, the histological structure of PFE increas-
es the risk of embolic episodes. Development of imaging techniques as well as their wider accessibility, 
especially TTE, contributes to the more common detection of this tumor in the general population. In this 
publication, we present a case of an asymptomatic 63-year-old woman in whom an aortic valve lesion 
resembling PFE was detected in TTE.
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Introduction
Cardiac tumors are rare. They are classified as 
primary (benign or malignant), and secondary (me-
tastases) that occur 20–40 times more frequently. The 
prevalence of primary cardiac tumors ranges from 
0.001%–0.03% [1]. Among them 75% are benign, which 
include PFE- the most common cardiac valves tumor, 
that is diagnosed in as many as 75% of such cases [4]. 
It is most often localized within the aortic valve (29%) 
[7]. Due to more frequent performing of transthoracic 
echocardiography (TTE) in the elderly population, the 
average age of detection of PFE is 60 years, but the 
tumor occurs in a wide age range (from newborns to 
elderly). It affects women and men equally often.
Case report
A 63-year-old female patient was admitted to the 
Department of Cardiology and Internal Medicine of Uni-
versity Hospital No. 1 in Bydgoszcz due to a suspected 
heart tumor. In outpatient TTE an additional echo in 
connection with the right coronary cusp of the aortic 
valve was visualized in the left ventricle outflow tract. The 
patient’s past medical history included paroxysmal atrial 
fibrillation, hypertension, subclinical hyperthyroidism, 
right internal carotid aneurysm, multifocal cerebrovas-
cular damage, and nicotinism. On admission, patient 
did not present stenocardial symptoms nor fever. 
Inflammation markers were within the normal range. 
Physical examination and other laboratory tests did not 
reveal abnormalities. The patient was on statin, aspirin, 
and thiamazole, without chronic anticoagulant therapy. 
Due to the CHAD2DS2-VASc score of 2 anticoagulation 
with apixaban 5 mg twice daily was introduced to the 
treatment. During the hospitalization blood cultures 
were collected for infective endocarditis - all returned 
negative. Transoesophageal echocardiography (TEE) 
revealed additional, mobile echo (1.2 cm x 0.7 cm) 
on a pedicle in connection with the right coronary 
cusp of the aortic valve (Fig. 1), without left ventricular 
outflow tract obstruction (LVOTO). Cardiac magnetic 
resonance (CMR) did not reveal a pathological mass 
in the aortic bulb nor the left ventricle outflow tract. 
Computed tomography (CT) of the heart with a sub-
millimeter layer was then performed. It confirmed the 
presence of a mass sized 2.5 cm x 4.0 cm x 5.5 cm on 
the ventricular surface of the right aortic cusp, which 
penetrated the left ventricle outflow tract and balloted 
together with the cusp (Figure 2). However, the above-
mentioned diagnostic tests did not allow to determine 
the nature of the lesion. Despite the asymptomatic 
clinical course, the patient was qualified for urgent 
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Figure 2. Papillary fibroelastoma of the heart. A. Cardiac computed tomography three-chamber view showing a polypoid 
lesion attached to the right coronary cusp. B. Axial reformatted image from conducted computed tomography demonstrates 
a small mass arising from the right coronary cusp. C. 3D-reconstruction showing papillary fibroelastoma attached to the 
right coronary cusp (yellow arrow). CT parameters: LVEF: 68 %; LVEDV: 106 ml; LVESV: 34 ml; SV: 72 ml
CT — computed tomography; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; 
LVESV — left ventricular end-systolic volume; SV — stroke volume
Figure 1. Papillary fibroelastoma in transesophageal echocardiography: A. midesophageal short axis 
of aortic valve view B. left ventricular outflow tract, long axis view. Echocardiographic parameters: 
LVEDD: 42 mm, LA: 33 mm, RV: 26 mm, LVEF: 60%, IVS: 11mm, PW: 11 mm, aortic PG max: 14 mm Hg 
LVEDD — left ventricular end-diastole diameter; LA — left atrium; RV — right ventricle; LVEF — left ventricular ejection 
fraction; IVS — interventricular septum thickness; PW — posterior wall thickness; PG max — maximum pressure gradient
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cardiac surgery. No significant stenoses were found in 
the routine pre-surgery coronary angiography. Next, the 
lesion was removed by aortotomy in the extracorporeal 
circulation. The tumor ( 1.2 cm x 0.7 cm x 0.4 cm) was 
excised completely without causing aortic valve defect, 
and after fixation in formalin, it was transferred to the 
Department of Clinical Pathomorphology of University 
Hospital No. 1 in Bydgoszcz for further examination. 
Light microscopy revealed a pedunculated lesion with 
numerous papillary branches made of acellular and 
avascular stroma covered with hyperplastic endocar-
dial endothelium (Figure 3). Based on the microscopic 
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assessment and clinical data, papillary fibroelastoma 
of the aortic valve has been diagnosed.
Discussion
PFE, after myxoma, is the second most common 
benign heart tumor [2, 3]. It is sometimes called as 
sea anemone, because of its undulating spines [5]. Its 
papillary protrusions are covered with regular endotheli-
um and their interior is built of amorphous, dense tissue 
rich in collagen and elastic fibers. The layered structure 
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Figure 3. Histological structure of the reported papillary 
fibroelastoma
of the tumor resembles normal chordae tendineae [6]. 
PFEs are usually small tumors that develop in the heart 
chambers, occupying individual heart valves according 
to the following frequency: aortic valve (29%), mitral 
valve (25%), tricuspid valve (17%) and pulmonary valve 
(13%) [7]. Their diameter ranges from 2 mm to 70 mm, 
with an average size of 9 mm [6].
The etiology of PFE is unclear and various possible 
causes have been proposed in the literature, such as 
prior damage to the endothelium, hamartomas and 
organized emboli. One of the most frequently quoted 
theories is the microthrombus theory, which states that 
tumors are acquired rather than congenital. [8, 9].
Although PFE histologically is a benign heart tumor, 
it can cause life-threatening embolic complications such 
as stroke, peripheral embolism, and myocardial infarc-
tion. Pulmonary embolism, congestive heart failure, ven-
tricular fibrillation, syncope and sudden cardiac death 
are rare, but also have been reported [2]. Although the 
most common location of PFE are heart valves, it rarely 
causes their dysfunction [10].
PFE can be easily detected by echocardiography. 
TTE is sufficient as a screening test, however, TEE is the 
preferred method due to its higher resolution and better 
imaging capability [11]. Given that PFE is an avascular 
tumor, the imaging of choice, in this case, is CMR. How-
ever, the sensitivity of CMR in PFE imaging depends on 
the imaging technique used (the appropriate number of 
projections, sequential gating, ECG gating).  Although 
there have been significant improvements in CMR and 
CT assessment of the cardiac valves, the time and 
spatial resolution are often inadequate to diagnose PFE 
due to its usually small size and mobile nature. This 
cause limitations of advanced imaging techniques in 
the diagnosis of the PFE.
On the basis of the described case, the authors 
noticed that there was a large discrepancy between the 
size of the tumor described in TEE and CT and the actu-
al size of the tumor found after surgical removal. Several 
CT technologic advances e.g. submillimeter detector 
arrays  increased rows of detectors, ECG gating- have 
resulted in improved imaging of cardiac  structures, 
including  cardiac  masses. The current limitations of 
this technique include, in addition to the significant 
radiation dose, a lower temporal resolution compared 
to echocardiography and cardiac MRI. Moreover, CT is 
inferior to echocardiography in imaging small moving 
structures, because it does not allow real-time imaging 
and the imaging planes are limited to those allowed by 
the angulation of the gantry [14] . 
Most PFEs are asymptomatic. Currently, there is 
no consensus on the treatment strategy of patients 
with PFE. Therapeutic decisions should take into ac-
count the severity of symptoms, location and size of 
the mass. Generally, symptomatic lesions should be 
treated by surgical excision of the tumor. Asymptom-
atic patients with lesions greater than 1 cm, that are 
mobile, and especially left-sided are also eligible for 
surgical resection because of the high risk of throm-
boembolic complications. However, if the masses are 
small, non-mobile, located on the left side of the heart, 
frequent echocardiographic assessment is sufficient. 
Small right-sided changes also should be monitored 
only. Despite the fact that no data exist on the evalu-
ation of the efficacy of anticoagulation or antiplatelet 
therapy in patients with PFE, tumor structure requires 
consideration of this treatment in patients treated con-
servatively [6, 12, 13].
This case report shows that more advanced imaging 
examinations (CMR and MDCT) are not always sensitive 
enough and TTE and TEE may constitute the basis for 
qualification for cardiac surgery.
Conclusions
TTE is a useful tool for screening and the initial 
diagnosis of a cardiac tumor. For further diagnosis or 
in the case of conflicting test results, other imaging 
methods should be performed (e.g. TEE, CMR, MDCT). 
The results obtained from imaging examinations have 
a direct impact on the choice of treatment. In par-
ticular, PFE needs to be differentiating from thrombi 
and cardiac myxomas because of the differences in 
their treatment. A clear surgical margin is necessary 
for the excision of a myxoma due to its high rate of 
recurrence. PFE rarely recur after resection, and so it 
is recommended to preserve the valvular function by 
shaving off the tumor. Although the TTE is widely used 
to screen for fibroelastomas, the TEE is more sensitive 
and can provide a higher resolution imaging for surgical 
planning. The importance of CMR and MDCT as tools in 
differential diagnosis of soft tissue masses of the heart 
is currently under investigation. 
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